Ország: Írország
Nyelv: angol
Forrás: HPRA (Health Products Regulatory Authority)
FRAMYCETIN SULFATE
Elanco Europe Ltd
QJ01GB
FRAMYCETIN SULFATE
150 Mg/Ml
Solution for Injection
POM
Bovine
Other aminoglycosides
Antibacterial
Authorised
2016-04-22
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Framomycin 150 mg/ml Solution for Injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: ACTIVE SUBSTANCE Framycetin Sulphate 150 mg (90,000 IU) Excipients Chlorocresol 1 mg Sodium metabisulphite (E223) 2 mg For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear, pale yellow solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dairy cows. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For use as an adjunct to intramammary therapy in the treatment of acute bacterial mastitis with systemic involvement, caused by organisms sensitive to framycetin in dairy cows. In vitro, framycetin has shown activity against _Escherichia_ _coli_, _Staphylococcus aureus_, _Arcanobacterium pyogenes _and _Klebsiella _spp. 4.3 CONTRAINDICATIONS Do not administer by the intravenous route, for intramuscular use only. Do not administer to animals known to be allergic to framycetin or other Streptomyces produced aminoglycosides, (e.g. streptomycin, gentamicin, kanamycin or neomycin). Hypersensitivity to framycetin may lead to cross reactions to other Streptomyces-produced aminoglycosides and vice versa. HEALTH PRODUCTS REGULATORY AUTHORITY ________________________________________________________________________________________________________________________ _Date Printed 22/04/2016_ _CRN 7023004_ _page number: 1_ 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None known. 4.5 SPECIAL PRECAUTIONS FOR USE I) SPECIAL PRECAUTIONS FOR USE IN ANIMALS The aminoglycosides can cause a fall in serum calcium levels: the concomitant use of calcium borogluconate infusions at the time of parturition may be advisable. Patients’ water intake should not be restricted during treatment. II) SPECIAL PRECAUTIONS TO BE TAKEN BY Olvassa el a teljes dokumentumot